“…It is also possible that the alterations in circulating extracellular NAMPT (eNAMPT) affects neuronal metabolic signals associated with hypothalamus, and is involved in the pathogenesis of systemic metabolic complications observed in ANKO mice (Imai and Yoshino, 2013; Yoon et al, 2015). Given previous findings demonstrating that reduction in adipose NAMPT expression and NAD + content is associated with obesity and its metabolic complications in people and rodents (Ando et al, 2005; Jukarainen et al, 2015; Kovacikova et al, 2008; Mercader et al, 2008; Xu et al, 2012; Yoshino et al, 2011), our data strongly suggest that impaired NAMPT-mediated NAD + biosynthesis in adipose tissue plays a causative role in the pathophysiology of obesity-associated metabolic derangements, and thereby could be an important therapeutic target. Indeed, recent studies have shown that systemic administration of NAD + intermediates, such as NMN and NR, improves insulin resistance, dyslipidemia, NAFLD, and glucose intolerance, in obese mice (Canto et al, 2012; Canto et al, 2015; Gariani et al, 2015; Imai and Yoshino, 2013; Yoshino et al, 2011).…”